Intracranial hypertension induced by rofecoxib
Research output: Contribution to journal › Article › peer-review
Colleges, School and Institutes
- University Hospitals of Leicester NHS Trust
Several secondary causes are implicated in the etiology of idiopathic intracranial hypertension. Rofecoxib is a selective cyclo-oxygenase (COX)-2 inhibitor, now being increasingly used in place of nonselective nonsteroidal anti-inflammatory drugs (NSAIDs). We report a case of intracranial hypertension in a 69-year-old man 3 weeks after the commencement of rofecoxib therapy with reversal of clinical findings on drug withdrawal.
|Number of pages||2|
|Publication status||Published - Jan 2005|
- Aged, Anti-Inflammatory Agents, Non-Steroidal/adverse effects, Arthritis, Rheumatoid/drug therapy, Cyclooxygenase Inhibitors/adverse effects, Humans, Intracranial Hypertension/chemically induced, Lactones/adverse effects, Male, Sulfones/adverse effects